MinervaX has partnered with Wacker Biotech to produce active protein ingredients for its Group B Streptococcus (GBS) vaccine, ...

Adults also need vaccines to protect against diseases like influenza, shingles, and pneumonia, especially susceptible individuals such as those with chronic diseases and healthcare workers.

MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS) and Wacker Biotech, a contract development and manufacturing ...

However, neither DRC nor other African nations produce the vaccines that could slow the spread of mpox and eventually help it ...

There is no general implemented and fully protective preventative treatment available for Group B Streptococcus.

MinervaX and Wacker Biotech announced yesterday that they have entered into a manufacturing agreement for MinervaX’s ...

Active pharmaceutical ingredients (API) for biologics are witnessing rapid growth as pharmaceutical companies focus on the development of advanced therapeutics. APIs biologics were traditionally ...

A vaccine is by far the most cost-effective way to tackle livestock methane emissions at scale within a reasonable timeframe, ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

Bavarian Nordic, a leading global supplier of travel vaccines, today announced the commercial availability of VAXCHORA®—the ...